IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Edwards Lifesciences Corp. won FDA approval for its Sapien 3 transcatheter heart valve device for aortic and mitral valve-in-valve procedures. The Irvine, Calif.-based company leads the way in a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
August 18, 2010 (Montreal, Quebec and Leicester, United Kingdom) — The best way to ensure that a patient who meets criteria for undergoing transcatheter aortic-valve replacement actually ends up ...
The FDA approved a new version of Edwards Lifesciences’ Sapien 3 transcatheter heart valve—coupling it with a self-expanding, stent-like device that helps reshape a malfunctioning pulmonary valve.
Hoag Memorial Hospital Presbyterian in Newport Beach will be among one of the first U.S. hospitals to offer a much-touted medical device from a device maker here. Irvine-based Edwards Lifesciences ...
Edwards Lifesciences is the global leader in medical devices for structural heart disease and critical care monitoring. Their Transcatheter Aortic Valve Replacement technology dominates the market and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results